Philadelphia Inquirer, The - Lawsuits target Vytorin's makers
First came the negative publicity, then the lawsuits. Merck & Co. and Schering Plough Corp., makers of the cholesterol-lowering combination drug Vytorin, are getting hit with a wave of lawsuits asserting the companies knew its product didn't work and delayed telling the public about it. At least 10 lawsuits have been filed in federal courts, with half the filings in New Jersey, where both parent companies are based.
Related Results
CORRECTIONS/CLARIFICATIONS
WALL STREET CHOICE: BEATING GUIDANCE WITH NEW DRUGS AND LOWER COSTS
Merck and Schering-Plough's statin combo hits pharmacies
New Study Showed VYTORIN Significantly More Effective than Crestor…
Vytorin study raises questions about Cholesterol’s Import
Other federal suits have landed in California, New York, Ohio and Colorado. The drugmakers “reaped billions of dollars in profits” by failing to release negative results, asserted a class-action complaint filed by a Philadelphia firm on behalf of Lionel D. Galperin of Washington state. The companies also caused patients to spend more money on Vytorin, which sells for more than $100 for 30 pills, compared with a lower-cost generic, the suit alleges. Skip Irvine, spokesman for the Merck-Schering Plough partnership, said the …
Read the full article with a Free Trial at MyWire.
